ZipLine Medical develops and commercializes non-invasive wound closure products centered on its Zip® Surgical Skin Closure system. The company sells its flagship Zip devices across surgical specialties including orthopedics, cardiovascular, and emergency medicine, and reports usage in over 500,000 cases in more than 30 countries. It is expanding its product portfolio with ZipStitch™, an over-the-counter laceration closure device, and PreLoc® Wound Closure for chronic wounds such as diabetic foot ulcers. ZipStitch—based on the same clinically proven technology—won a 2018 Medical Design Excellence Award in the Over-the-Counter and Self-Care Products category and is available for purchase online. The company intends to use new financing to continue worldwide commercialization and support these product launches. ZipLine Medical was founded by Amir Belson, M.D., and is headquartered in Campbell, CA. ZipLine Medical is a medical device company that developed the Zip® Surgical Skin Closure device, a cost-effective, noninvasive skin-closure system delivering suture-like outcomes at the speed of staples. The company intends to accelerate worldwide commercialization and expand global sales and marketing following its recent financing. Clinical studies (knee arthroplasty at Hospital for Special Surgery and a pacemaker study at UCSD) showed fewer wound complications versus staples, procedure-time savings versus sutures, and suture-like cosmetic outcomes. The Zip device has been used in over 25,000 surgical procedures and is sold in over 30 countries. ZipLine estimates its addressable market at $4 billion worldwide; its devices are classified by the U.S. FDA as Class I, 510(k) Exempt and have received CE Mark. Founded by Amir Belson and headquartered in Campbell, CA, the company plans to leverage favorable clinical results and key opinion leader support to grow commercial adoption. ZipLine Medical develops the Zip® Surgical Skin Closure, a noninvasive device designed to deliver suture-like outcomes at the speed of staples while reducing surgical-site infection risk and hospital costs. The devices are classified by the U.S. FDA as Class I, 510(k) Exempt and have received CE Mark. Because skin closure is common to nearly all surgical procedures, ZipLine says its product has applicability across multiple medical specialties. The company estimates an addressable market opportunity of $4 billion worldwide. ZipLine is headquartered in Campbell, Calif., was founded by Amir Belson, MD, and is led by President and CEO John Tighe. Management plans to use proceeds from the Series C extension to expand sales and marketing activities and to support geographic expansion, including into China. ZipLine Medical is an emerging medical device company developing cost-effective, noninvasive surgical skin-closure devices (Zip™) intended to provide suture-like cosmetic outcomes with the speed of stapling and reduced surgical site infection risk. Its Zip™ Surgical Skin Closure devices are classified by the U.S. FDA as Class I, Exempt and have applicability across multiple medical specialties. The company estimates its addressable market at $4 billion worldwide. Preliminary randomized, controlled clinical data presented at the Mount Sinai Winter Symposium showed similar cosmetic outcomes versus traditional sutures and a 57% reduction in wound closure procedure time. ZipLine was founded in 2009 by Amir Belson, M.D., and is headquartered in Campbell, Calif. Proceeds from the recent financing will be used to expand sales and marketing efforts. ZipLine Medical is an emerging medical device company that has developed the PRELOC (Pre-placementRE-aligning Low-tensionClosure) platform for noninvasive surgical skin closure. PRELOC is designed to provide a suture-like outcome with the speed of staples via a simple, easy-to-learn and easy-to-use device. The company says the platform has broad applicability across numerous medical specialties because skin-closure is a common denominator of almost all surgeries; initial target applications include C-section, laparotomy, pacemaker/ICD implant, laparoscopic port, orthopedic, and excisional skin biopsy closure. ZipLine cites a $4.2 billion worldwide market opportunity covering most surgical procedures involving skin incision. The company is headquartered in Campbell, Calif., and in Q3 2011 appointed John R. Tighe as President and CEO. ZipLine closed a $5M Series B in Q3 2011 and has total funding of $6M; proceeds are being used to complete product development and establish commercial operations.

Total raised

$43M

Funding rounds

5

Latest round

Equity

Latest activity

Jun 2018